quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:23:20·45d
SECFiling
Zevra Therapeutics Inc. logo

SEC Form 10-K filed by Zevra Therapeutics Inc.

ZVRA· Zevra Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ZVRA
    Zevra Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 16UpdateBTIG Research$23.00
  • Jul 2UpdateH.C. Wainwright$26.00
  • Jan 8UpdateCantor Fitzgerald$25.00
  • Oct 7UpdateGuggenheim$20.00
  • Sep 24UpdateJMP Securities$17.00
  • Sep 24UpdateMaxim Group$25.00

Related

  • PR2d
    Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
  • SEC3d
    SEC Form DEF 14A filed by Zevra Therapeutics Inc.
  • SEC17d
    SEC Form PRE 14A filed by Zevra Therapeutics Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Zevra Therapeutics Inc.
  • INSIDER28d
    SEC Form 4 filed by Bode John B
  • PR34d
    Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER35d
    SEC Form 4 filed by Renz Justin A
  • INSIDER35d
    SEC Form 3 filed by new insider Renz Justin A
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022